Dalton to Support US Army Drug Development Program
The contract service provider entered into a contract agreement with the US Army to provide services in the development of treatments of malaria.
On Dec. 20, 2016, Dalton Pharma Services, a Health Canada-approved and FDA-registered current good manufacturing practice (cGMP) contract service provider of integrated chemistry, drug development, and manufacturing services, announced that it has entered into an agreement with the US Army Medical Material Development Activity (USAMMDA). Dalton will offer services, which include cGMP sterile powder filling, aseptic liquid filling, quality control release testing, and International Council for Harmonization (ICH) stability services, to the USAMMDA’s anti-malarial drug development program. USAMMDA, as part of the US Department of Defense, develops new drugs, vaccines, and medical support equipment to protect and treat military personnel.
“The leadership role taken by USAMMDA in the development of this important therapy for malaria treatment is to be commended, and we are privileged to support this critical program developing safe and effective anti-malarial drugs for emergency treatment protocols,” said Peter Pekos, president and CEO of Dalton, in a press release.
Source: Dalton Pharma Services
